FR2512344A1 - Procede de fabrication d'une suspension stable d'hydroxyde d'alumine et/ou d'hydroxyde de magnesie comme agent actif des antacida - Google Patents
Procede de fabrication d'une suspension stable d'hydroxyde d'alumine et/ou d'hydroxyde de magnesie comme agent actif des antacida Download PDFInfo
- Publication number
- FR2512344A1 FR2512344A1 FR8117018A FR8117018A FR2512344A1 FR 2512344 A1 FR2512344 A1 FR 2512344A1 FR 8117018 A FR8117018 A FR 8117018A FR 8117018 A FR8117018 A FR 8117018A FR 2512344 A1 FR2512344 A1 FR 2512344A1
- Authority
- FR
- France
- Prior art keywords
- mixture
- hydroxide
- particle size
- magnesium hydroxide
- dispersed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 title claims abstract description 21
- 239000000725 suspension Substances 0.000 title claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 5
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 title abstract description 7
- 239000000347 magnesium hydroxide Substances 0.000 title abstract description 7
- 229910001862 magnesium hydroxide Inorganic materials 0.000 title abstract description 7
- 239000003159 antacid agent Substances 0.000 title abstract description 6
- 229910021502 aluminium hydroxide Inorganic materials 0.000 title abstract 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title description 6
- 229940069428 antacid Drugs 0.000 title description 5
- 230000001458 anti-acid effect Effects 0.000 title description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 title 1
- 239000000499 gel Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000006185 dispersion Substances 0.000 claims abstract description 6
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 12
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 11
- 239000000395 magnesium oxide Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 238000013467 fragmentation Methods 0.000 claims description 3
- 238000006062 fragmentation reaction Methods 0.000 claims description 3
- 150000004679 hydroxides Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 7
- 230000002496 gastric effect Effects 0.000 abstract description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract description 5
- 230000003472 neutralizing effect Effects 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 3
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 230000003113 alkalizing effect Effects 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 9
- 159000000011 group IA salts Chemical class 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 1
- 229940110321 dicyclomine hydrochloride Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8117018A FR2512344A1 (fr) | 1981-09-08 | 1981-09-08 | Procede de fabrication d'une suspension stable d'hydroxyde d'alumine et/ou d'hydroxyde de magnesie comme agent actif des antacida |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8117018A FR2512344A1 (fr) | 1981-09-08 | 1981-09-08 | Procede de fabrication d'une suspension stable d'hydroxyde d'alumine et/ou d'hydroxyde de magnesie comme agent actif des antacida |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2512344A1 true FR2512344A1 (fr) | 1983-03-11 |
| FR2512344B1 FR2512344B1 (https=) | 1983-12-02 |
Family
ID=9261968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8117018A Granted FR2512344A1 (fr) | 1981-09-08 | 1981-09-08 | Procede de fabrication d'une suspension stable d'hydroxyde d'alumine et/ou d'hydroxyde de magnesie comme agent actif des antacida |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2512344A1 (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0286978A1 (en) * | 1987-04-15 | 1988-10-19 | Lisapharma Spa | Pharmaceutical compositions in the form of stable sucralfate suspensions free of suspending agents |
| WO1994013304A3 (en) * | 1992-12-11 | 1994-09-01 | Sterling Winthrop Inc | Antacid composition and method of production |
| WO1994021268A1 (en) * | 1993-03-16 | 1994-09-29 | Synepos Aktiengesellschaft | Aluminium containing pharmaceutical preparation with controlled release |
| US5455050A (en) * | 1993-11-12 | 1995-10-03 | Mcneil-Ppc, Inc. | Aqueous antacids with calcium carbonate and magnesium salt |
| US5874112A (en) * | 1997-03-31 | 1999-02-23 | Mcneil Ppc-Inc. | Translucent antacid suspension |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1126105A (en) * | 1966-06-10 | 1968-09-05 | Armour Pharma | Antacids and process of making the same |
-
1981
- 1981-09-08 FR FR8117018A patent/FR2512344A1/fr active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1126105A (en) * | 1966-06-10 | 1968-09-05 | Armour Pharma | Antacids and process of making the same |
Non-Patent Citations (3)
| Title |
|---|
| CA1959 * |
| CA1971 * |
| CA1974 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0286978A1 (en) * | 1987-04-15 | 1988-10-19 | Lisapharma Spa | Pharmaceutical compositions in the form of stable sucralfate suspensions free of suspending agents |
| WO1994013304A3 (en) * | 1992-12-11 | 1994-09-01 | Sterling Winthrop Inc | Antacid composition and method of production |
| WO1994021268A1 (en) * | 1993-03-16 | 1994-09-29 | Synepos Aktiengesellschaft | Aluminium containing pharmaceutical preparation with controlled release |
| US5455050A (en) * | 1993-11-12 | 1995-10-03 | Mcneil-Ppc, Inc. | Aqueous antacids with calcium carbonate and magnesium salt |
| US5631026A (en) * | 1993-11-12 | 1997-05-20 | Mcneil-Ppc, Inc. | Aqueous antacids with calcium carbonate and magnesium salt |
| US5874112A (en) * | 1997-03-31 | 1999-02-23 | Mcneil Ppc-Inc. | Translucent antacid suspension |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2512344B1 (https=) | 1983-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0107559B1 (fr) | Procédé d'homogénéisation de dispersions de phases lamellaires lipidiques hydratées | |
| BE891088R (fr) | Composition a base de peroxyde de benzoyle | |
| Collins et al. | Bioadhesive lozenge for the improved delivery of cetylpyridinium chloride | |
| BE901672A (fr) | Procede de purification de proteines du lait et de ses derives. | |
| WO2003053417A2 (fr) | Procede de fabrication d'un comprime incluant un analgesique de type morphinique et comprime obtenu | |
| FR2542735A1 (fr) | Resinate d'un acide carboxylique substitue, procedes pour sa preparation, son utilisation et compositions pharmaceutiques le contenant | |
| JPH1036276A (ja) | 抗アレルギー剤及びこれを含有する抗アレルギー性化粧料並びに食品 | |
| EP1196185A1 (fr) | Nouvelle utilisation de solutions salines hypoosmotiques et medicament a base de ces solutions | |
| EP1000608A1 (fr) | Poudre cosmétique et/ou dermatologique, son procédé de préparation et ses utilisations | |
| FR2512344A1 (fr) | Procede de fabrication d'une suspension stable d'hydroxyde d'alumine et/ou d'hydroxyde de magnesie comme agent actif des antacida | |
| WO2021253803A1 (zh) | 一种清火片的制备方法 | |
| FR2675020A1 (fr) | Produit solide contenant des composants de propolis, preparation et applications. | |
| RU2382636C2 (ru) | Композиция сиропа, включающая дексибупропен в качестве активного ингредиента, и способ ее получения | |
| DE3338978A1 (de) | Verapamil und gallopamil und ihre physiologisch vertraeglichen salze zur resorptiven anwendung auf den schleimhaeuten des mundes, des nasen-rachen-raums und des rektums | |
| JP3693754B2 (ja) | チロシナーゼ活性阻害剤 | |
| CN107349375B (zh) | 一种中药口服微乳剂的制备方法及中药口服微乳剂 | |
| CN1265784C (zh) | 经皮肤给药的组合物 | |
| RU2093140C1 (ru) | Лечебно-профилактическая помада и способ ее приготовления | |
| CN117643558A (zh) | 一种含有艾叶油微囊漱口水的制备方法 | |
| RU2102972C1 (ru) | Водная эмульсия перфторуглеродов | |
| CA2691398A1 (fr) | Composition dermatologique comprenant des vesicules lipidiques de calcitriol, son procede de preparation et son utilisation | |
| EP0911038A1 (fr) | Composition anhydre à base de lactulose | |
| TWI843562B (zh) | 朝鮮薊萃取物用以製備治療阿茲海默症的藥物的用途 | |
| EP0350438B1 (fr) | Composition à usage cosmétique ou pharmaceutique | |
| CN1292728C (zh) | 复方芦荟微乳组合物及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |